Vol 2, No 1 (March 10, 2013): Chinese Clinical Oncology

Editorials

Can EGFR mutation status evolve with chemotherapy?
Eric S. Kim, David J. Stewart, Alok A. Khorana
Chinese Clinical Oncology  
2013;
2
(1)
:1
.
EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy
Jair Bar, Damien Urban, Roni Borshtein, Hovav Nechushtan, Amir Onn
Chinese Clinical Oncology  
2013;
2
(1)
:2
.
Drifting EGFR mutation
Rintaro Noro, Tesshi Yamada
Chinese Clinical Oncology  
2013;
2
(1)
:3
.

Original Article

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments
Laura E. Johnson, Jordan T. Becker, Jason A. Dubovsky, Brian M. Olson, Douglas G. McNeel
Chinese Clinical Oncology  
2013;
2
(1)
:4
.

Review Articles

Molecular therapy for gastric cancer
Yasuhide Yamada
Chinese Clinical Oncology  
2013;
2
(1)
:5
.
Current status and future direction of chemotherapy for pancreatic cancer
Junji Furuse, Fumio Nagashima
Chinese Clinical Oncology  
2013;
2
(1)
:6
.
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention
Patrick A. Ott, F. Stephen Hodi
Chinese Clinical Oncology  
2013;
2
(1)
:7
.
Colorectal cancer screening: are stool and blood based tests good enough?
Chung-Wah Wu, Joseph Jao-Yiu Sung
Chinese Clinical Oncology  
2013;
2
(1)
:8
.
The future of clinical research in oncology: where are we heading to?
Denis Lacombe, Yan Liu
Chinese Clinical Oncology  
2013;
2
(1)
:9
.

Perspective

Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant
Valerie Nelson, Alfred Rademaker, Virginia Kaklamani
Chinese Clinical Oncology  
2013;
2
(1)
:10
.